# An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

> **NCT06946199** · PHASE1 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 28 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Cizutamig
- **BIOLOGICAL:** Cizutamig

## Key facts

- **NCT ID:** NCT06946199
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946199, "An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06946199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*